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Identification and characterization of CKLiK, a novel granulocyte
Ca11/calmodulin-dependent kinase
Sandra Verploegen, Jan-Willem J. Lammers, Leo Koenderman, and Paul J. Coffer
Human granulocytes are characterized
by a variety of specific effector functions
involved in host defense. Several widely
expressed protein kinases have been im-
plicated in the regulation of these effector
functions. A polymerase chain reaction–
based strategy was used to identify novel
granulocyte-specific kinases. A novel pro-
tein kinase complementary DNA with an
open reading frame of 357 amino acids
was identified with homology to calcium-
calmodulin–dependent kinase I (CaMKI).
This has been termed CaMKI-like kinase
(CKLiK). Analysis of CKLiK messenger
RNA (mRNA) expression in hematopoi-
etic cells demonstrated an almost exclu-
sive expression in human polymorpho-
nuclear leukocytes (PMN). Up-regulation
of CKLiK mRNA occurs during neutro-
philic differentiation of CD341 stem cells.
CKLiK kinase activity was dependent on
Ca11 and calmodulin as analyzed by in
vitro phosphorylation of cyclic adenosine
monophosphate responsive element
modulator (CREM). Furthermore, CKLiK-
transfected cells treated with ionomycin
demonstrated an induction of CRE-
binding protein (CREB) transcriptional ac-
tivity compared to control cells. Addition-
ally, CaMK-kinasea enhanced CKLiK ac-
tivity. In vivo activation of CKLiK was
shown by addition of interleukin (IL)-8
to a myeloid cell line stably expressing
CKLiK. Furthermore inducible activa-
tion of CKLiK was sufficient to induce
extracellular signal-related kinase (ERK)
mitogen-activated protein (MAP) kinase
activity. These data identify a novel
Ca11/calmodulin-dependent PMN-
specific kinase that may play a role in
Ca11-mediated regulation of human
granulocyte functions. (Blood. 2000;96:
3215-3223)
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Introduction
Human polymorphonuclear leukocytes (PMN), which include
neutrophilic and eosinophilic granulocytes, play an important role
in host defense against invading microorganisms.1 Recruitment and
activation of these cells in vivo occur in a multistep process that
involves many different membrane-bound receptors activating an
array of diverse intracellular signaling molecules. In short, PMNs
in the peripheral blood enter a preactivated state by interacting with
cytokines liberated from the inflammatory locus. This is followed
by attachment to the endothelium, which is mediated by the
interaction with adhesion molecules expressed on the surface of
activated endothelial cells. Release of chemokines at the site of
inflammation is responsible for the migration of PMNs to this
locus. Finally on recognition of the inciting agent by PMNs,
phagocytosis, secretion of toxic proteins, and activation of mem-
brane-bound NADPH-oxidase generating reactive oxygen interme-
diates ensues.2,3 Furthermore, rapid induction of apoptosis in
PMNs and subsequent removal of apoptotic cells are important in
the rapid resolution of inflammation.4,5 An unfortunate conse-
quence of activation in vivo is tissue damage during acute
inflammation and, therefore, the activity of granulocytes is under
tight control.
The PMNs express a wide variety of receptors on their plasma
membranes, steering the process of priming and activation. On
binding of inflammatory mediators, such as formyl peptides,
lipopolysaccharides, chemokines, or cytokines, the receptor trans-
mits a signal to the cell interior resulting in the initiation of a
cascade of intracellular events. Phosphorylation of effector mol-
ecules by kinases is critical for transducing intracellular signals.
Thus far several classes of kinases, including (1) serine kinases,
such as mitogen activated (MAP) kinases; (2) lipid kinases such as
phosphatidylinositol-3 kinase (PI-3K); (3) tyrosine kinases includ-
ing the src kinases; (4) cyclic adenosine monophosphate (cAMP)-
dependent kinases, and (5) Ca11-dependent kinases, are activated
in response to inflammatory mediators in human granulocytes.
A role for these widely expressed kinases in neutrophil func-
tions has been intensively studied using pharmacologic inhibitors.
A role for MAP kinases, p42ERK1 and p42ERK2, in chemotaxis,
respiratory burst, and platelet activating factor (PAF) release is
suggested, although the use of a pharmacologic inhibitor for
MAPK/ERK kinase (MEK) has resulted in contradictory find-
ings.6,7 A clearer role for PI-3K in neutrophil migration and
respiratory burst has been demonstrated by use of PI-3K inhibitors
wortmannin and LY294002.7-11 A role for protein kinase C (PKC)
has also been postulated in a variety of granulocyte effector
functions and protein kinase A (PKA) is suggested to be involved in
down-regulating the respiratory burst.12,13 Recently a role for src
kinases in adhesion-dependent degranulation has also been de-
scribed.14 Although inhibitory studies support a role for these
kinases in regulating neutrophil functions, their activation is not
specific for these granulocyte effector functions because they are
widely expressed. Furthermore, pharmacologic inhibitors are often
limited in their specificity, making the interpretation of data more
complex.15
Changes in cytosolic free Ca11 are described during activation
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of several neutrophil responses, such as degranulation, respiratory
burst, and adhesion. An important role for Ca11 in these processes
has been suggested16,17 and, therefore, Ca11-dependent kinases
may well be involved. In addition a role for the Ca11-dependent
phosphatase, calcineurin has been shown in the Ca11-dependent
recycling of integrins to the front of migrating neutrophils,18
whereas a role for calmodulin and CaMKII is suggested in oxygen
production.19
In this report we describe the identification of a novel protein
kinase, which we have termed CKLiK (CaMKI-like kinase). This
kinase is predominantly expressed in human PMNs and is regu-
lated by Ca11 and calmodulin. Interleukin (IL)-8, which is a potent
activator of neutrophil effector functions, induces activation of
CKLiK and we show that an inducible active mutant of CKLiK
induces ERK MAP kinase activation. These data identify a novel
Ca11/calmodulin-dependent protein kinase expressed in PMNs
that may play a role in transducing chemokine-induced signals
regulating human granulocyte functions.
Materials and methods
Cells, reagents, and antibodies
The COS cells were cultured in Dulbecco modified Eagle medium (Life
Technologies, Breda, The Netherlands) supplemented with 8% heat-
inactivated fetal calf serum (FCS). CD341 stem cells were cultured in
Iscove modified Dulbecco medium (IMDM) supplemented with 2 mmol/L
glutamine, 8% Hyclone, and cytokines. Murine myeloid 32D cells were
cultured in RPMI 1640–glutamate supplemented with 8% Hyclone serum
(Life Technologies) and mouse IL-3.20 The 32D cells were stably trans-
fected with pBabe-HA_CKLiK by electroporation (0.26 V, 1000 msec, 100
mFD) and selected with puromycin (1 mg/mL; Sigma, Zwijndrecht, The
Netherlands) at a concentration of 1 mg/mL. Ionomycin was purchased
from Calbiochem (La Lolla, CA). Calmodulin was a kind gift of Dr R. de
Groot. Monoclonal antibodies, 12CA5 against HA epitope, were purchased
from Boehringer Mannheim Biochemicals (Almere, The Netherlands).
Polyclonal anti-VSV tag antibodies were obtained from Medical &
Biological Laboratories (MBL, Nagoya, Japan). Human IL-8, trombopoetin
(TPO), fms-like tyrosine kinase-3 (FLT-3) ligand, and stem cell factor
(SCF) were purchased from PeproTech (Rocky Hill, NJ). Human IL-3 and
granulocyte colony-stimulating factor (G-CSF) were purchased from
Strathmann Biotech (Hamburg, Germany) and IL-6 was purchased from
Roche Molecular Biochemicals (Indianapolis, IN). Phospho-CREB-Ser133
antibodies were obtained from New England Biolabs (Beverly, MA).
4-Hydroxy-tamoxifen and W7 were purchased from Sigma; PD098059 was
purchased from Biomol (Plymouth Meeting, PA).
Identification and cloning of granulocyte kinases
For the identification of novel kinases in human granulocytes polymerase
chain reaction (PCR) was performed using degenerate primers as previ-
ously described.21 Forward primers were based around the consensus amino
acid (single-letter symbols) sequence HRDLKPEN, which corresponded to
the conserved regions in the serine/threonine protein kinase catalytic
domain. Oligonucleotides were also designed against the DXWXXG amino
acid motif approximately 65 amino acids downstream and used as reverse
primers. PCR was performed on granulocyte complementary DNA (cDNA)
with Taq polymerase (Perkin Elmer, Roche Molecular Systems, Branch-
burg, NJ) using excess of degenerate primers (1 mg) under conditions of 10
mmol/L Tris-Cl pH 8.3, 50 mmol/L KCl, 0.2 mmol/L dNTPs, and 0.8
mmol/L MgCl2. Denaturation, annealing, and extension temperatures of
94°C, 52°C, and 72°C, respectively, were used. PCR products of approxi-
mately 200 bp were cloned into pGEM-T vector (Promega, Madison, WI)
and sequenced. The identified sequences were screened against the BLAST
database (http: //www.ncbi.nlm.nih.gov/BLAST).
Full-length cDNA was obtained by screening a lZAPII eosinophilic
library22 with the amplified PCR fragment as a probe. After plaque
purification, the pBluescript SK2 phagemids containing positive inserts
were isolated by in vivo excision using M13K07 helper phages (Promega),
and subsequently characterized by restriction mapping and sequencing.
Isolation of human leukocytes
Blood was obtained from healthy volunteers at the donor service of the
University Medical Centre (Utrecht, The Netherlands). Granulocytes were
isolated from blood treated with 0.4% (wt/vol) trisodium citrate (pH 7.4) as
previously described.23 Mononuclear cells were removed from granulo-
cytes by centrifugation over isotonic Ficoll from Pharmacia (Uppsula,
Sweden). After lysis of the erythrocytes in an isotonic NH4Cl solution,
neutrophils were washed and resuspended in incubation buffer (20 mmol/L
HEPES, 132 mmol/LM NaCl, 6 mmol/L KCl, 1 mmol/L MgSO4, 1.2
mmol/L KH2PO4, 5 mmol/L glucose, 1 mmol/L CaCl2). Granulocytes were
incubated for 30 minutes at 37°C before experiments were performed.
Monocytes were further separated from mononuclear lymphocytes by
elutriation as described previously.24
Isolation and differentiation of CD341 stem cells
The CD341 cells were isolated using the MACS CD341 progenitor cells
isolation kit from Miltenyi Biotech (Auburn, CA). First, mononuclear cells
were isolated from human umbilical cord blood cells by density centrifuga-
tion over a Ficoll solution. Cells were blocked and additionally incubated
with a CD34 antibody in a phosphate buffer containing 2 mmol/L EDTA
and 0.5% bovine serum albumin (BSA) (buffer M). Magnetic beads
recognizing the CD34 antibody were added and the suspension was applied
to an MS1 separation column placed in the magnetic cell separator
MiniMACS. CD342 cells were allowed to pass through the column by 3
wash steps with buffer M. CD341 cells were eluted with buffer M by
removal of the column from the separator. To obtain a pure CD341 cell
population the magnetic separation step was repeated on a second column.
After final elution stem cells were counted and cultured. Before differentia-
tion, CD341 stem cells were proliferated for 1 week in the presence of TPO
(10 ng/mL), SCF (50 ng/mL), FLT-3 ligand (50 ng/mL), and IL-6 (2
ng/mL). At day 0 differentiation was started by addition of SCF, FLT-3
ligand, IL-3 (10 ng/mL), and G-CSF (30 ng/mL). At days 3, 7, 10, 14, and
17, IL-3 and G-CSF were added and at day 21 only G-CSF was added to the
cells. At each point cells were counted, diluted to 0.5 3 106 cells/mL and, if
possible, samples were taken for mRNA isolation.
RNase protection
Total mRNA from human monocytes, lymphocytes, granulocytes, and
hematopoietic cell lines HL60, U937, and THP1 were isolated. In short, 108
cells were lysed in 2 mL GIT-C solution (6 mol/L guanidine thiocyanate, 25
mmol/L sodium citrate, 0.5% N9-lauroyl-sacosine, 100 mmol/L b-mercap-
toethanol), and RNAs were further isolated by phenol extraction and
ethanol precipitation. 32P-UTP–labeled antisense RNA transcript, corre-
sponding to the original PCR fragment coding the catalytic domain of
CKLiK, was generated using the Riboprobe in vitro transcription system
(Promega) and used as an RNA probe. As internal control a 90-bp antisense
RNA probe of GAPDH was used. Total RNA samples (10 mg) were
lyophilized and resuspended in 2 mL diethyl pyrocarbonate (DEPC) water.
Hybridization was performed with 105 cpm of each antisense RNA probe in
25 mL 80% formamide, 40 mmol/L PIPES pH 6.4, 400 mmol/L NaCl, and 1
mmol/L EDTA overnight at 45°C. Subsequently probes were incubated for
1 hour in RNAse buffer (10 mmol/L Tris-Cl pH 7.5, 5 mmol/L EDTA, 300
mmol/L NaCl supplemented with 0.15 mL/mL T1 RNase) at 37°C to
degrade unhybridized RNA. The reaction was stopped by addition of 10 mL
proteinase K (5 mg/mL) and 10% sodium dodecyl sulfate (SDS). Hybrid-
ized (double-stranded) RNA was purified by phenol extraction and ethanol
precipitation. The remaining pellet was resuspended in 2 mL DEPC water
and 2 mL RNA loading buffer (80% formamide, 10 mmol/L EDTA, 1
mg/mL xylene cyanol, 1 mg/mL bromphenol blue). Samples were heated
for 5 minutes at 95°C and analyzed by polyacrylamide gel electrophore-
sis (PAGE).
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DNA constructs
Epitope-tagged CKLiK was generated by PCR using the oligonucleotides
forward XhoI; 59-CCGCTCGAGTATGGCCCGGGAGAACGGC-39 and
reverse KpnI; 59-CCGGTACCCAAGTAG-CTGACATTACAGG-59) and
ligated by XhoI/KpnI digest into pMT-HA. HA_CKLiK-309 and HA_CK-
LiK-296 were also generated by PCR using reverse primers introducing a
stop codon at amino acid 310 or 297 309:59-GCATTTCATGCTTGGCAC-
CATT-39,296; 59-GCTCTAGATCA-CTGGGCGCTGACGGACTC-39).
PCR products were cloned into pGEM-T vector and subcloned into
pMT2-HA vector. Green fluorescent protein (GFP)-tagged CKLiK was
generated by PCR and recloned in frame into pEGFP-C2 vector (Clontech
Laboratories, Palo Alto, CA). HA_CKLiK was cloned from pMT-HA into
pBabe25 by BamHI/ EcoRI digest. Untagged CKLiK-296 was obtained by
PCR and cloned into pSG5.26 VSV-tagged CaMKKa was generated by
PCR on rat brain tissue cDNA using the oligonucleotides 59-CAGTCGAC-
CAGGAATATCCACGGACTGA-39 and 59-ATAGCGGCCGCC-GGATG-
CAGCCTCATCTTC-39 and cloned into the pMT2-VSV vector. Tamoxifen-
inducible CKLiK construct, ER_CKLiK-296, was generated by PCR and
cloned into the pCDNA3-ER-N vector. The constructs for HA_PKB and
HA_ERK have been previously described.27 CREB_GAL4,
CREBS133A_GAL4, and GAL4CAT constructs were previously
described.28
In vitro kinase assay
The COS cells were transiently transfected with 10 mg of HA-tagged
CKLiK-WT, CKLiK-309, or CKLiK-296 using calcium phosphate precipi-
tation, and the medium was refreshed 16 hours later. For the CKLiK kinase
assay, 24 hours later cells were stimulated with or without ionomycin for 5
minutes, washed twice with cold phosphate-buffered saline (PBS) and lysed
in a buffer containing 1% NP-40, 20 mmol/L Tris-Cl pH 7.5, 150 mmol/L
NaCl, 10% glycerol, and 10 mmol/L MgCl2 supplemented with 10 mg/mL
aprotinin, 1 mmol/L leupeptin, 1 mmol/L PMSF, 1 mmol/L benzamidine,
and 1 mmol/L Na3VO4. The 32D cells stably expressing CKLiK-WT were
mIL-3 and serum starved for 4 hours and stimulated with hIL-8 (1027
mol/L). Cells were washed and lysed in buffer described above. Lysates
were precleared for 20 minutes with protein-A beads and immunoprecipi-
tated with 12CA5 antibody. Immunoprecipitates were washed twice in lysis
buffer and twice in dilution buffer containing 10 mmol/L Tris-Cl pH 7.4 and
20 mmol/L MgCl2. Kinase assay was performed in the presence of 10
mmol/L Tris-Cl pH7.4, 20 mmol/L MgCl2, 1 mmol/L DTT, 50 mmol/L ATP,
0.1 mL 32P-dATP in the presence or absence of 1 mmol/L CaCl2 and 0.5 mg
calmodulin, 5 mg CREMb (33 kd), or mutated CREMt-S117A (42 kd) as
substrate.29 Protein kinase B (PKB) and ERK kinase assay were performed
as described previously.27
CAT assay
The COS cells were transiently transfected with 4 mg CKLiK-WT, -309, or
-296, together with 2 mg CREB_GAL4 or CREB-S133A_GAL4 fusion
expression plasmids and 2 mg GAL4CAT reporter construct using calcium
phosphate precipitation. After 16 hours cells were washed twice and
medium refreshed. Eight hours later cells were incubated overnight with 1
mmol/L ionomycin. Cells were lysed by repeated freeze-thawing in 100 mL
250 mmol/L Tris-Cl pH7.4 and 25 mmol/L EDTA. Then, 50mL of cellular
extract was incubated in a total volume of 100 mL containing 250 mmol/L
Tris-Cl 7.4, 2% glycerol, 0.3 mmol/L butyryl coenzyme A, and 0.05 mCi
14C-chloramphenicol for 2 hours at 37°C. Reaction products were extracted
using 400 mL xylene/pristane 1:2 and the percentage of acetylated products
was determined using liquid scintillation counting. A lacZ reporter was used
to correct for transfection efficiency. Data represent at least 3 independent
experiments 6 SEM.
Detection of GFP fusion-protein localization
Plasmids encoding CKLiK and active CKLiK-296 containing N-terminal
enhanced GFP were transiently transfected in COS cells that were grown on
coverslips. Thirty-six hours after transfection COS cells were washed with
PBS, fixed with 70% ice-cold methanol, and examined by fluores-
cence microscopy.
Western blotting
After stimulation 106 neutrophils/point were lysed in 1 3 Laemmli sample
buffer. Protein samples were separated by SDS-PAGE and transferred to
polyvinylidene difluoride membranes (Immobilon-P, Millipore, Bedford,
MA). The membranes were probed with antiphospho-CREB-Ser133 anti-
bodies (New England Biolabs) and swine antirabbit peroxidase-conjugated
antibodies (DAKO, Glostrup, Denmark), following detection by enhanced
chemiluminescence (ECL, Amersham-Pharmacia, Biotech, The Nether-
lands). Protein kinase expression controls were performed by using 12CA5
and rabbit antimouse peroxidase-conjugated antibodies (DAKO) to detect
HA_CKLiK, HA_ERK, and HA_PKB. Detection of CaMKK-VSV was
performed with anti-VSV antibodies and swine antirabbit peroxidase-
conjugated antibodies. Hybridizations were followed by detection with
ECL (Amersham).
Results
Cloning and expression of CKLiK
Although several kinases have been implicated in the control of
granulocyte effector functions,12,30 most of these proteins are
widely expressed. To identify novel granulocyte-specific kinases,
degenerate primers against conserved kinase catalytic domains
were used as previously described.21 The central core of the
catalytic domain consists of subdomains VI and IX and contains 2
well-conserved amino acid triplets APE and DGF.31 Degenerate
oligonucleotides were designed against subdomains VI and IX and
used in a PCR on cDNA of human PMNs. Under stringent
conditions PCR products of approximately 200 bp were amplified,
cloned, and sequenced. All cloned PCR products contained the 2
conserved amino acid triplets and many were identical to previ-
ously identified kinases (data not shown). However, one clone
exhibited homology with calcium/calmodulin-dependent kinase I
(CaMKI) and subsequently termed CKLiK (CaMKI-like kinase).
To isolate full-length CKLiK cDNA, a human eosinophil library
was screened with the amplified PMN cDNA PCR fragment.
Several positive clones were isolated and sequenced, and one
cDNA of 1.7 kb contained a 357 amino acid open reading frame
encoding a protein of 40 kd as determined by in vitro transcription/
translation (data not shown). In Figure 1 the complete cDNA and
the translated amino acid sequence is depicted (accession number
AF286366). The context of the ATG codon was in good agreement
with eukaryotic translation start-sites.32 As shown in Figure 2A,
comparison of the predicted CKLiK protein sequence in BLAST
database revealed a 77% homology of CKLiK with CaMKI on the
amino acid level. The greatest divergence between the 2 sequences
occurs at the N- and C-termini.
To determine the distribution of CKLiK expression we analyzed
mRNA levels in primary human leukocytes and hematopoietic cell
lines by RNase protection (Figure 2B). The mRNAs from lympho-
cytes, which include T and B cells, monocytes, and PMNs, were
analyzed. Additionally, 3 myeloid cell lines HL60 (promyelocytic
leukemia), U937 (histiocytic lymphoma), and THP1 (acute mono-
cytic leukemia) were analyzed for CKLiK expression. As an
internal control we used a GAPDH probe (Figure 2B; lower panel).
Human PMNs contain high levels of CKLiK (Figure 2B; lane 3),
whereas little to no expression was observed in monocytes and
lymphocytes (Figure 2B; lanes 1 and 2). In the different lymphoid
and myeloid cell lines we could not detect CKLiK (Figure 2B;
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lanes 4-6). Because CKLiK expression is apparently only detected
in mature myeloid cells, we analyzed the expression of CKLiK
during differentiation of CD341 cord blood stem cells toward the
neutrophilic lineage. Although after 10 days of differentiation
CKLiK mRNA was present, increased mRNA levels are indeed
detected during terminal differentiation at day 28 (Figure 2C).
Similar results were obtained during the differentiation toward
eosinophils in the presence of IL-5 (data not shown).
CKLiK kinase activity is dependent on Ca11/calmodulin and
can regulate CREM and CREB
As mentioned, CKLiK has homology with the Ca11/calmodulin-
dependent kinase family. The CaM kinases belong to the serine/
threonine class of kinases and include CaMKI, CaMKIV, and the
upstream CaMKK.33 To investigate whether Ca11 and calmodulin
regulated CKLiK we used CRE-binding protein (CREB) or CRE
modulator (CREM) as downstream targets. CREB and CREM
belong to the basic-leucine-zipper (bZip) class of transcription
factors. Serine 133 for CREB and serine 117 for CREM are
phosphorylated by several kinases including CaMKI in vitro,28,34
resulting in interaction with transcriptional coactivators and induc-
tion of transcription.35
CKLiK kinase activity was analyzed by in vitro kinase assay,
using CREM as a substrate and by transcriptional reporter assays
using CREB_GAL4 fusion constructs.28 CKLiK was immunopre-
cipitated from transfected COS cell lysates and immunocomplex
kinase assays performed (Figure 3A). CREMb (33 kd) or a mutant
CREMt (42 kd), which has a serine to an alanine substitution on
position 117 (CREMt-S117A), were used as substrates (Figure
3A). Because of the different size of the 2 isoforms, this allows the
Figure 2. CKLiK is homologous to CaMKI and highly expressed in human
granulocytes. (A) Alignment of CKLiK with CaMKI. Residues identical to CaMKI are
indicated by an asterisk (*) and gaps in the alignment are indicated with a dash
(2).The amino acid sequence is indicated on the right. (B) Distribution of CKLiK was
determined by RNase protection. The PCR product encoding the catalytic domain of
CKLiK was used to generate a radiolabeled RNA probe. RNA isolated from primary
hematopoietic cells and cell lines were hybridized for CKLiK expression. A GAPDH
probe was used as a control. Lanes 1 to 3 represent primary leukocytes (1,
lymphocytes; 2, monocytes; 3, PMNs) and lanes 4 to 6 represent lymphoid and
myeloid cell lines as indicated. (C) Expression of CKLiK in cord blood-derived CD341
stem cells during differentiation toward neutrophils was analyzed by RNase protec-
tion as in panel B. Time points indicate the number of days differentiated toward
neutrophilic lineage in the presence of G-CSF.
Figure 1. CaMKI-like kinase, CKLiK, nucleotide sequence, and open reading
frame. Full-length sequence of the novel kinase was obtained by screening an
eosinophil cDNA lZAPII phage library using the initial degenerate PCR product as a
probe. Sequencing was performed and the open reading frame was analyzed.
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specific phosphorylation of S-117 to be analyzed within a single
assay. The assay was performed in the absence or presence of Ca11
and calmodulin. As a positive control for this assay we used
recombinant CaMKI, which potently phosphorylated CREMb.
Because of the high level of recombinant CaMKI, some back-
ground phosphorylation of the mutated form of CREM (CREMt-
S117A) was detected. A clear phosphorylation of CREMb but not
CREMt-S117A by CKLiK was observed in the presence of
Ca11/calmodulin and this was enhanced by prior ionomycin
treatment (Figure 3A). A small activation of CKLiK was also
observed by ionomycin treatment in the absence of Ca11/
calmodulin during the kinase assay (data not shown). For transcrip-
tional reporter assays, cells were transfected with HA_CKLiK, a
GAL4-CAT reporter construct, in combination with a CREB-
_GAL4 fusion construct or a mutant thereof, in which the
phosphorylation site (S-133) is substituted by an alanine (CREB-
S133A_GAL4) (Figure 3B). Ionomycin treatment resulted in a
5-fold induction of reporter activity in cells expressing CKLiK
with only a modest increase in control cells (Figure 3B; left panel).
CKLiK had no effect when using the mutant form of CREB (Figure
3B; right panel). These results demonstrate that CKLiK is regulated
by Ca11/calmodulin and that active CKLiK can directly phosphor-
ylate CREM and activate CREB, enhancing its transactiva-
tion capacity.
C-terminal truncation of CKLiK results in a constitutively
active mutant
Sequence alignment with CaMKI and the results described above
suggests that CKLiK contains a calmodulin-binding domain regu-
lating its activity. To investigate this hypothesis we generated 2
truncation mutants (Figure 4A). Truncation of the predicted
calmodulin-binding domain (CKLiK-309) should result in an
inactive kinase. Indeed mutant CKLiK-309, lacking residues 310 to
357, remains inactive even in the presence of Ca11/calmodulin,
unable to phosphorylate CREM (Figure 4B) or to activate CREB-
mediated transcription after ionomycin stimulation (Figure 4C).
However, if CKLiK also contains an autoinhibitory domain similar
to CaMKI, then removal of this domain (CKLiK-296) should
generate a constitutively active kinase. As was predicted, trunca-
tion of residues 297 to 357 generated a constitutively active
CKLiK. CREM was phosphorylated by CKLiK-296 in the absence
of Ca11/calmodulin (Figure 4B) and CKLiK-296 greatly enhanced
CREB-mediated transcription, which was not further enhanced by
ionomycin addition (Figure 4C).
Because we demonstrated that activated CKLiK could phosphor-
ylate CREM and activate CREB-mediated transcription, we were
interested in determining whether CKLiK was located in the
cytoplasm or nucleus. We generated GFP containing fusion con-
structs of CKLiK-WT and the active CKLiK-296. COS cells were
grown on coverslips and transfected with CKLiK and CKLiK-296
containing N-terminal GFP fusion. Localization was examined by
fluorescence microscopy (Figure 4D). GFP-CKLiK was clearly
located in the cytoplasm, whereas the active form of CKLiK
exhibited a strong nuclear fluorescence. Because the active form of
Figure 4. A constitutively active CKLiK mutant activates CREB and CREM
independently of Ca11 /calmodulin. (A) Schematic representation of the predicted
calmodulin-binding domain (CBD) and the autoinhibitory domain (AID) of CKLiK.
Truncation mutants of these 2 domains are indicated. In CKLiK-309 the predicted
CBD and in CKLiK-296 the predicted CBD and AID were deleted. (B) In vitro kinase
assays. COS cells were transfected with 10 mg HA_CKLiK-WT (wt), HA_CKLiK-309
(309), or HA_CKLiK-296 (296) as indicated. Immunoprecipitations were performed
and CREM phosphorylation was detected in the presence or absence of Ca11/
calmodulin as indicated. Expression of the different forms of CKLiK was detected by
Western blotting of cell lysates with 12CA5 antibody. (C) Reporter assays. Cells were
transfected with GAL4-CAT reporter construct, CREB-GAL4 (2 mg) and cotransfected
with CKLiK-WT or mutated CKLiK-309 or CKLiK-296 (4 mg) as indicated. Eighteen
hours before harvesting, cells were stimulated with (u) or without (M) 1 mmol/L
ionomycin and reporter assays were performed. Data represent at least 3 indepen-
dent experiments 6 SEM and were corrected for transfection efficiency. (D) Active
CKLiK is localized in the nucleus. Cells were grown on coverslips and transfected
with CKLiK and active CKLiK-296 containing N-terminal enhanced green fluorescent
protein (eGFP). Thirty-six hours after transfection cells were examined by fluores-
cence microscopy for CKLiK localization.
Figure 3. CKLiK activity requires Ca11/Calmodulin and regulates the transcrip-
tion factors CREM and CREB. (A) COS cells were transfected with 10 mg
HA_CKLiK. Recombinant CaMKI was used as a positive control. Cells were
stimulated with or without 1 mmol/L ionomycin as indicated. HA_CKLiK was
immunoprecipitated from whole cell lysates and kinase assays were performed in the
presence or absence of Ca11/calmodulin as indicated. CREMb-WT (33 kd) and
mutated CREMt-S117A (42 kd) were used as substrate. Data represent 1 of 4
independent experiments. (B) Cells transfected with GAL4-CAT reporter construct (2
mg) and fusion construct of CREB_GAL4 or CREB-S133A_GAL4 (2 mg) (indicated as
CREB-WT and CREB-S133A, respectively), were cotransfected with CKLiK (4 mg) or
with control vector as indicated. Stimulation with or without 1 mmol/L ionomycin and
CAT reporter assays were performed as described in “Materials and methods.” Data
are indicated as counts per minute (cpm) and represent at least 3 independent
experiments 6 SEM.
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CKLiK is detected in the nucleus, it suggests that CKLiK may
regulate transcription through nuclear localization.
Ca11/calmodulin kinase kinasea enhances CKLiK activity
Although the binding of Ca11/calmodulin is known to activate
CaM kinases, an additional activation of CaMKI and CAMKIV by
CAMK kinase (CAMKK) has previously been described.36-38
CaMKK phosphorylates CAMKI and CaMKIV in the activation
loop at position T-177 and T-196/T-200 respectively, stabilizing
and thereby enhancing kinase activity. CKLiK contains a threonine
at position 180 in alignment with T-177 of CaMKI and T-200 of
CAMKIV. To investigate the effect of CAMKKa on the CKLiK
activity we performed kinase and reporter assays. Cotransfection of
CaMKKa with CKLiK resulted in an enhanced CREM phosphory-
lation (Figure 5A; right panel). In the absence of Ca11/calmodulin
in the kinase assay, CaMKKa enhanced CKLiK-induced CREM
phosphorylation (Figure 5A; left panel). Similar results were found
using reporter assays (Figure 5B). Cotransfection of CKLiK with
CaMKKa resulted in an elevated reporter activity both in untreated
(Figure 5B; left panel) and ionomycin-treated cells (Figure 5B;
right panel). CaMKKa alone had no effect on CAT activity,
suggesting that CaMKKa cannot itself activate CREB directly.
Interestingly CaMKKa can enhance CKLiK activity in the absence
of Ca11 in the in vitro kinase assay. Indeed there are indications for
CaMKKa-induced CaMK activity in the absence of Ca11 and
calmodulin33,.39 However, Ca11/calmodulin is present in the trans-
fected cells, and phosphorylation of CKLiK by CaMKKa may lead
to stabilization of the CKLiK/Ca11/calmodulin complex, resulting
in enhanced kinase activity.
Activation of CKLiK by IL-8 in bone marrow–derived myeloid
precursor cells
Because agonist stimulation of G protein–coupled receptors results
in changes of [Ca11]i, these receptors are potential activators of
CKLiK. The IL-8 receptor is highly expressed on human neutro-
phils and IL-8 can activate neutrophil effector functions, such as
chemotaxis. To investigate whether IL-8 can activate CKLiK, we
used a 32D model system. The 32D cells are IL-3–dependent
myeloid precursor cells derived from bone marrow.40 Because
these cells express endogenous IL-8R41 we generated stable 32D
cell lines expressing HA_CKLiK and used these cells to measure
IL-8–induced CKLiK activity. IL-8 was indeed able to induce an
increase in intracellular Ca11 in these cells (Figure 6A). IL-8
stimulation of HA_CKLiK-expressing 32D cells resulted in a rapid
transient increased CKLiK activation (Figure 6B), whereas in
Ca11-depleted cells, IL-8–induced CKLiK activity was completely
Figure 6. IL-8 stimulation of bone marrow–derived myeloid precursor cells
activates CKLiK. (A) Ca11 response of 32D cells to hIL-8 (1027 mol/L). Cells were
incubated with INDO-AM for 45 minutes and washed twice. [Ca11]i concentrations
were measured by dual excitation at a wavelength of 340 nm and detected at 390 nm
using a Hitachi F4500 fluorescence spectrophotometer. Digitonin was added for
100% [Ca11]i as indicated. (B) IL-8 induces CREB phosphorylation in 32D cells
stably expressing wild-type HA_CKLiK. Cells were starved for 4 hours and stimulated
with IL-8 (1027 mol/L) for indicated time periods. HA-tagged CKLiK was immunopre-
cipitated and kinase assays performed in the absence of Ca11/calmodulin using
CREM as a substrate. Ionomycin-treated and untransfected 32D cells were used as
positive and negative controls, respectively. Data represent 1 of at least 3 indepen-
dent experiments. (C) W7 inhibits CKLiK kinase activity. HA_CKLiK stable 32D cells
were starved and treated for 15 minutes with or without the calmodulin inhibitor W7
prior to IL-8 (102 mol/L) stimulation. Immunocomplex kinase assays were performed
as in (B).
Figure 5. CaMKKa enhances CKLiK activity. (A) HA_CKLiK (8 mg) was transfected
in COS cells with or without CaMKKa_VSV (2 mg). Before harvesting, cells were
stimulated with or without 1 mmol/L ionomycin as indicated. HA_CKLiK was
immunoprecipitated and kinase assays were performed using CREM as substrate in
the presence or absence of Ca11/calmodulin. Equal protein expression was
demonstrated by Western blotting. For CKLiK antibody 12CA5 (middle panel) and for
CaMKKa antibody anti-VSV (bottom panel) is used. (B) CREB_GAL4 and CKLiK (4
mg) were cotransfected without or with CaMKKa (2 mg) as indicated. CaMKKa was
transfected without CKLiK as a negative control. Eighteen hours before harvesting,
cells were stimulated with or without 1mmol/L ionomycin and reporter assays were
performed. Data represent at least 3 independent experiments 6 SEM and are
corrected for transfection efficiency.
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abolished (data not shown). CKLiK activation parallels the rise in
intracellular Ca11 induced by IL-8 (Figure 6A). In addition, W7,
an antagonist of calmodulin, completely inhibited the IL-8–
induced CKLiK activity (Figure 6C). CKLiK activity was also
inhibited by W7 in the ionomycin-treated cells, indicating that
calmodulin is indeed critical for the CKLiK kinase activity
stimulated by agents, which induce a Ca11 influx.
Activation of downstream signaling pathways by CKLiK
To identify potential downstream targets of CKLiK, we analyzed
the effect of CKLiK on the activation of the ERK1 MAP kinase and
PKB, an effector of PI-3K. The regulation of ERKs and PKB by
[Ca11]i has been demonstrated in several systems.42,43 Cells were
transfected with HA-tagged ERK or PKB and cotransfected with
constitutively active CKLiK (CKLiK-296) or CaMKKa and immu-
nocomplex kinase assays were performed. Stimulation with 20%
FCS for 10 minutes was used as a positive control. Cotransfection
of CKLiK-296 had no effect on PKB activity, whereas cotransfec-
tion of CaMKKa potently activated PKB similar to levels induced
by 20% FCS (Figure 7A; upper panel). This is in agreement with
the direct PKB phosphorylation by CaMKK described by Yano and
colleagues.42 Interestingly, however, cotransfection of constitu-
tively active CKLiK-296 resulted in an increase in ERK1 activa-
tion (Figure 7A; lower panel). To avoid the possibility of autocrine
effects due to overexpression of active CKLiK, we constructed a
tamoxifen-inducible active CKLiK (ER_CKLiK-296). When trans-
fected into cells, ER_CKLiK-296 is actively repressed by binding
of heat-shock proteins. On addition of the estrogen derivative,
4-hydroxy-tamoxifen (4-OHT), heat-shock proteins dissociate and
CKLiK-296 is directly activated.44 This system has been success-
fully used for other protein kinases.45 Cells were transfected with
ER_CKLiK-296 and HA epitope–tagged ERK1 or PKB. Before
harvesting, cells were stimulated with 4-OHT and ERK/PKB
kinase activity was measured. After 2 minutes of treatment an
increased ERK activation was detected, whereas no PKB activation
occurred (Figure 7B). The CKLiK-induced ERK activity could be
blocked by the MEK inhibitor PD098059 (Figure 7C), suggesting
that CKLiK activates signaling molecules upstream in the MAPK
pathway. Thus, these results suggest a role for CKLiK in regulation
of ERK MAPK kinases at the level of MEK or higher.
Discussion
We have described the identification and characterization of a novel
protein serine kinase that is highly expressed in human PMNs.
These cells, which include neutrophils and eosinophils, are charac-
terized by a variety of specific effector functions that regulate host
defense. Although several protein kinases have been previously
postulated to regulate some of these effector functions through
pharmacologic inhibition studies, these proteins are ubiquitously
expressed and thus more likely to be involved in general cellular
processes. Furthermore, the use of pharmacologic inhibitors is
often complicated by nonspecific effects15,46
By using degenerate PCR primers against conserved catalytic
kinase domains in PCR on cDNA templates from human granulo-
cytes, we have identified a novel protein kinase with an open
reading frame of 357 amino acids (Figure 1). This novel kinase
shows homology with calcium/calmodulin-dependent kinase I
(CaMKI) and therefore we have termed this kinase CaMKI-like
kinase (CKLiK). CaMKI belongs to the family of Ca11-and
calmodulin-dependent kinases, which includes CaMK I, II, and IV
as well as myosin light chain kinase, phosphorylase kinase, and
elongation factor 2 kinase.47,48 CaMKI has a wide tissue distribu-
tion and can phosphorylate a number of substrates in vitro,
including the synaptic vesicle-associated proteins synapsin 1 and
synapsin 249 and CREB.28 Interestingly, analysis of CKLiK mRNA
in hematopoietic cells revealed high and almost exclusive expres-
sion levels in PMNs, suggesting a role for CKLiK in human
granulocytes (Figure 2). Up-regulation of CKLiK mRNA was also
observed in cord blood CD341 stem cells differentiated toward
neutrophils, which may indicate the importance of this kinase in
terminally differentiated myeloid cells. In granulocytes, changes in
[Ca11]i have been associated with multiple functions, including
degranulation, phagosome-lysosome fusion, regulation of cytoskel-
etal binding proteins, and transcriptional control.16,17 These are thus
potential processes whereby CKLiK may play a role.
Based on crystal structure and mutational analysis of CamKI, a
model has been proposed for CaMKs regulation.50,51 When Ca11
levels rise within the cytosol, calmodulin binds Ca11 and is
capable of interacting with calmodulin-binding proteins such as
CaMK. Inactive CaMKs are in a folded configuration whereby the
N-terminus acts as a pseudosubstrate by interacting with an
autoinhibitory domain. On Ca11 recruitment, calmodulin binds to
the calmodulin-binding domain located on the C-terminal of
CaMK, which then results in unfolding and autophosphorylation of
CaMK. It appears that CKLiK is also similarly regulated because
truncation of the predicted calmodulin-binding domain or the
autoinhibitory domain resulted in an inactive and constitutively
active CKLiK, respectively (Figure 4).
Figure 7. CKLiK activates ERK1 MAP kinase but not PKB. (A) HA_PKB or
HA_ERK1 (2 mg) was transfected in COS cells with or without CaMKKa (8 mg) or
CKLiK-296 (8 mg) as indicated. Twenty hours before harvesting cells were serum
starved. Unstimulated and 20% FCS-treated cells were used as controls. HA_PKB or
HA_ERK were immune precipitated and kinase activity was measured using histone
2B (H2B) or myelin basic protein (MBP) as a substrates. Data represent 1 of at least 4
independent experiments. (B) HA_ERK1 or HA_PKB (2 mg) was cotransfected with
ER_CKLiK-296 (8 mg) in COS cells. Before harvesting, cells were stimulated with
4-OHT for 2 or 10 minutes. Immunoprecipitations and kinase assays were performed
as in panel A using H2B or MBP as a substrate. Equal expression of HA_PKB and
HA_ERK were analyzed by Western blotting of whole cell lysates with 12CA5
antibody. (C) PD098059 inhibits the CKLiK-induced ERK activity. COS cells were
transfected with HA_ERK1 (2 mg) and ER_CKLiK-296 (8 mg). Cells were treated with
or without the MEK inhibitor PD098059 (50 mmol/L) for 15 minutes before stimulation
with 4-OHT for indicated time periods. Cells were lysed and immunocomplex kinase
assays were performed as previously described. Equal expression of HA_ERK1 was
analyzed by Western blotting.
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Additionally we show that CKLiK can directly activate 2
members of the CREB/ATF family of transcription factors, CREM
and CREB, by phosphorylation of serine residues 117 and 133,
respectively (Figure 3). Although CKLiK is located in the cyto-
plasm, the constitutively active mutant was clearly translocated to
the nucleus (Figure 4D). Possibly this enhanced nuclear transloca-
tion uncouples CKLiK from normal regulation resulting in en-
hanced transcriptional activation. For CaMKIV it has been sug-
gested that it can phosphorylate CREB in vivo because it shows
nuclear localization.52 Although a role for CREB in myeloid cells
has been proposed in mediating cytokine or chemokine effector
functions,53-56 it remains to be determined if CREB and CREM are
physiologic substrates for CKLiK in human granulocytes. Indeed
we were able to demonstrate CREB phosphorylation by IL-8 in
human PMNs (data not shown).
Cotransfection of CaMK kinase (CaMKKa) resulted in an
enhanced CKLiK activity measured by in vitro phosphorylation of
CREM and in vivo CREB-mediated transcription activation.
Enhancement of CKLiK activity by CaMKK is possible via
phosphorylation of the threonine residue on position 180, because
this is in consensus with threonine residues 177 and 196/200 of
CaMKI and CaMKIV, respectively. Interestingly CaMKKa in-
duced CKLiK activity in the absence of Ca11 in the in vitro kinase
assay (Figure 5). There is indication of the generation of Ca11-
independent CaMKIV activity by CaMKKa; however, this is not
the case for CaMKI.33,39 What the mechanism is for generating this
enhanced CKLiK activity is unclear, although this may be irrel-
evant in vivo. It may be due to stabilization of the CKLiK/Ca11/
calmodulin complex allowing, for example, a prolonged kinase
activity similar to the regulation of CaMKII,57 which might be
needed for regulation of transcription.
The IL-8–induced CKLiK activation was rapid and corre-
sponded to the IL-8–induced rise in [Ca11]i (Figure 6). The IL-8
receptor is highly expressed on human neutrophils and could be a
possible upstream physiologic receptor for CKLiK. IL-8 is known
to induce chemotaxis, and recently a role for intracellular Ca11 in
IL-8–induced migration has been described indicating a possible
role of CKLiK in this process.58,59 A role for Ca11 and calmodulin-
dependent kinases in apoptosis has also been recently demonstrated
because CaMKK was found to directly activate PKB and thereby
rescue apoptosis.42 Although we found no activation of PKB by
CKLiK, we demonstrated an elevated ERK activity by inducing
CKLiK activation, which could be blocked by the MEK inhibitor
PD098059 (Figure 7). As previously alluded to, pharmacologic
inhibitory studies have suggested that ERK MAP kinases possibly
play a role in chemotaxis or respiratory burst and PAF release.6,7,60
The mechanism by which CKLiK can activate ERKs however
remains to be resolved, although it presumably occurs upstream
of ERK.
In conclusion, the approach of degenerate PCR resulted in a
successful isolation of a novel PMN protein kinase. We have
demonstrated that this kinase is highly and predominantly ex-
pressed in human PMNs and terminally differentiated myeloid
stem cells and that Ca11/calmodulin regulates its activity. IL-8,
which is a potent activator of neutrophil effector functions, is
capable of activating CKLiK in bone marrow-derived myeloid
cells. Furthermore, a role for CKLiK is suggested in regulation of
ERK MAP kinases because induced CKLiK activity was sufficient
to activate ERK1. Therefore, the restricted expression of CKLiK in
granulocytes can allow the transduction of granulocyte-specific
signals induced by a general signal transduction event: the rise in
[Ca11]i, initiated by inflammatory mediators.
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